Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Regeneron Pharmaceuticals lifted by quarterly eye drug sales

Friday, November 4, 2016 8:17
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Drug developer Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares added almost 4% in New York as it posted good quarterly sales growth of its key eye drug Eylea.

Sales of the treatment in the three months increased 16% to US$854mln compared to US$734 million in the same period a year ago.

And the pharma group now expects Eylea to post between 23% and 25% revenue growth for the year as a whole – more than the low end of its forecast by 3%.

But overall, the firm’s revenue reportedly grew at the slowest pace in more than four years.

In the three months, Regeneron posted a profit of US$265mln, or $2.27 on a per-share basis, up from $210mln, or $1.82 a share a year earlier.

Revenue rose 7.3% to US$1.22 billion. Thomson Reuters analysts had expected adjusted earnings per share of $2.71 on revenue of $1.29 billion.

In the quarter, Regeneron’s research and development costs increased 28% to $543 million, it added

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.